LLY
Eli Lilly and Company
LLY has the edge over TNDM overall, supported by lower modeled downside and stronger fundamentals.
TNDM
Tandem Diabetes Care, Inc.
TNDM's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TNDM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TNDM's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TNDM PE Valuation
TNDM has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TNDM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TNDM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TNDM on earnings quality, reporting a profit while its opponent remains loss making.
TNDM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.72 | +$2.33 |
| Q2 2026 | -$0.93 | +$2.16 |
| Q1 2026 | -$1.40 | +$1.38 |
| Q4 2025 | -$3.07 | -$1.61 |
| Q3 2025 | -$3.05 | -$1.12 |
| Q2 2025 | -$3.09 | -$1.00 |
| Q1 2025 | -$2.78 | -$0.61 |
| Q4 2024 | -$1.46 | +$1.98 |
TNDM is still losing money, but far less than before: $0.72 per share over the past year, against $3.48 at its worst in mid-2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TNDM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TNDM on profitability, with a higher operating margin.
TNDM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $283.7M | +14% |
| Q2 2026 | $254.6M | +5.8% |
| Q1 2026 | $247.2M | +5.5% |
| Q4 2025 | $290.4M | +2.7% |
| Q3 2025 | $249.3M | +2.2% |
| Q2 2025 | $240.7M | +8.5% |
| Q1 2025 | $234.4M | +22% |
| Q4 2024 | $282.6M | +44% |
TNDM's revenue has grown year over year for 11 quarters in a row: $284M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | +8.3 points |
| Q2 2026 | -5.4% | +16 points |
| Q1 2026 | -7% | +45 points |
| Q4 2025 | 2.9% | +3.1 points |
| Q3 2025 | -9.2% | +1.5 points |
| Q2 2025 | -22% | -7.7 points |
| Q1 2025 | -52% | -30 points |
| Q4 2024 | -0.2% | +18 points |
TNDM's operating margin was −0.8% last quarter, up 8.3 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TNDM on cash generation, producing positive trailing cash flow while its opponent burns cash.
TNDM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.5M | -232% |
| Q2 2026 | -$38.7M | -$23M |
| Q1 2026 | $4.8M | +$26M |
| Q4 2025 | $3.1M | -59% |
| Q3 2025 | $4.2M | -81% |
| Q2 2025 | -$15.7M | -$4M |
| Q1 2025 | -$21.2M | -$8.8M |
| Q4 2024 | $7.6M | +$20.1M |
TNDM's free cash flow was −$36M over the past year, against −$25M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TNDM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TNDM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +639K shares |
| 1 year | +3% | +2M shares |
| 3 years | +7% | +4.5M shares |
| 5 years | +7.5% | +4.9M shares |
| Available history | +19% | +11.1M shares |
TNDM has 70M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $30M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TNDM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -16.5x | Net Cash |
| Q1 2022 | -3.8x | Net Cash |
| Q4 2021 | -2.0x | Net Cash |
| Q3 2021 | -2.7x | Net Cash |
| Q2 2021 | -3.0x | Net Cash |
| Q1 2021 | -8.3x | Net Cash |
| Q4 2020 | -37.9x | Net Cash |
TNDM has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TNDM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 30.2 | Neutral |
TNDM's weekly RSI is 48 (neutral) and its Stochastic is 30 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TNDM PE vs Healthcare Sector
| Metric | TNDM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TNDM has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TNDM on trend strength, trading above more of its moving averages.
TNDM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.9 | 3.4% above |
| 20 week MA | $18.1 | 3.4% below |
| 50 week MA | $19.1 | 8.4% below |
| 100 week MA | $19.9 | 12% below |
| 200 week MA | $26.5 | 34% below |
TNDM has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 34% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TNDM on returns for 2026, with the stronger performance.
TNDM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.2 | $93.9 | +56% |
| 2021 | $93.9 | $151.8 | +62% |
| 2022 | $151.8 | $42.0 | -72% |
| 2023 | $42.0 | $29.6 | -30% |
| 2024 | $29.6 | $36.9 | +25% |
| 2025 | $36.9 | $22.4 | -39% |
| 2026 YTD | $22.4 | $17.5 | -22% |
TNDM has finished lower in three of the last six years. It's down 22% so far in 2026.